Notes

Developments inside TREC beliefs in accordance with grow older and sex in Oriental young children in addition to their specialized medical programs.
To observe and analyze the effect of dexmedetomidine on analgesia and sedation of sufentanil during anesthesia induction period of gynecological surgery. A total of 160 patients demanding gynecologic surgery were enrolled in the study and randomly divided into study group and control group, each containing 80 patients. The control group was treated with sufentanil and normal saline, while the study group was treated with sufentanil and dexmedetomidine. Then, the therapeutic effect of the two groups was compared. NTI of the two groups was observed at A2, which was significantly lower in the study group than that in the control group. Moreover, NTI value of the two groups was significantly lower at A2 and A4 than at A1. When the NTI value was reduced to a minimum, the application time was significantly shorter in the study group than that in the control group. PTO and PPT of the two groups were higher at A4 than those at A1. At A1 and A4, The difference between PTO and PPT was significantly higher in the study group than that in the control group, p less then 0.05. The rate of adverse reactions was significantly lower in the study group than that in the control group, p less then 0.05. HG-9-91-01 nmr Dexmedetomidine has good effect on analgesia and sedation of sufentanil during anesthesia induction period of gynecological surgery, which should be popularized in clinical application.Puerarin is an important active ingredient of Radix puerariae. Puerarin is an isoflavone compound Z clinical and basic research proves that S. puerarin can increase cerebral circulation blood flow; increase cerebral perfusion; reduce blood viscosity and improve microcirculation. The present research was conducted to observe the clinical efficacy of puerarin combined with naloxone in the treatment of traumatic cerebral infarction (TCI). Methods 52 patients with TCI were randomly divided into two groups. The treatment group was treated with puerarin and naloxone and the control group was treated with conventional therapy. Results The total effective rate was 82% in the treatment group, which was better than 61% in the control group. The difference was statistically significant (p less then 0.05). The efficacy of simple TCI in both groups was significantly better than that of TCI with brain contusion; the effect of intracranial hemorrhage and the effect of TCI alone in the two groups; the treatment group was significantly better than the control group (p less then 0.05). Conclusion The combination of puerarin and naloxone in the treatment of TCI can improve the curative effect.As a α1-adrenergic receptor antagonist, nicergoline can induce vasodilation and increase arterial blood flow. Its clinical application can effectively prevent and treat cognitive impairment and reduce cognitive decline and comprehensively improve patients' daily living ability and social function. The clinical efficacy of nicergoline combined with oxiracetam in the treatment of vascular cognitive impairment after stroke was analyzed. 120 patients with cognitive impairment after stroke were randomly divided into nicergoline group and Experience group. They were treated with nicergoline and nicergoline combined with oxiracetam respectively. Both groups were treated for one month. Montreal Cognitive Assessment Scale (MoCA) was used to evaluate the cognitive function of the two groups before and after treatment, and the clinical efficacy was compared. The results showed that the average score of MoCA in the combined group was (5.97±2.06), higher than that in the nicergoline group (3.53±1.44). The change of MoCA score was the most significant. There was significant difference between the nicergoline group and the combined group (t=4.21, P less then 0.01). The combined group had the highest effective rate and the total effective rate was 93.3%. Conclusion Nicergoline and oxiracetam are effective drugs in the treatment of vascular cognitive impairment (VCI). The combined use of nicergoline and oxiracetam is better than that of nicergoline alone. The combined use of nicergoline and oxiracetam can significantly improve the severity of symptoms and quality of life in patients with vascular cognitive impairment after stroke. The clinical effect is definite.As a new oral anticoagulant, rivaroxaban is equivalent to warfarin in preventing and treating thromboembolism, but it can significantly reduce the occurrence of severe bleeding and fatal organ bleeding. This article analyzes the clinical efficacy and drug safety of rivaroxaban in the prevention and treatment of senile thromboembolic disease. The results showed that after treatment, acute thrombosis disappeared in patients with acute venous thrombosis, and no new or recurrent venous thrombosis, pulmonary embolism and death occurred. In the rivaroxaban group, 3 cases of fecal occult blood were positive at 6 months and the incidence rate was 7%. During the follow-up period, there were no significant changes in laboratory blood tests for coagulation, hemoglobin, platelet and liver and kidney function during the follow-up observation of the rivaroxaban group and between the rivaroxaban group and the warfarin group (P>0.05). Therefore, oral rivaroxaban is an effective method for the prevention and treatment of elderly patients with thromboembolic disease. Daily 10mg rivaroxaban is a safe and effective dose for the prevention and treatment of elderly patients with thrombotic diseases. The efficacy of rivaroxaban is equivalent to that of warfarin. However, the treatment is easier with better compliance and safety.Inflammatory response that occur post-ischemia is a serious problem in the treatment of ischemic brain disease. MicroRNA-155 is a brain-specific or brain-enriched miRNA, which mediates inflammatory reactions in cerebral ischemic tissue by regulating inflammatory signal and the expression level of SOCS1. The present study was aimed to assess the effect of GuaLou GuiZhi Decoction (GLGZD) on miR-155 expression in activated microglia following inflammation and further explore the role of GLGZD on expression of the inflammation-related gene. BV2 cells were used to simulated by LPS to make the inflammatory model. Expression level of miR-155 was detected by Real-Time PCR. BV2 cells after simulated by LPS were then transfected with miR-155 mimic and its negative controls. Cytokines release were measured by corresponding purchased ELISA kits, respectively. Then target protein expression of miR-155 were detected by western blotting assay. After miRNA over expression transfections, expressions of inflammation-related factors, SOCS-1 and SAMD in BV2 cells after activation were measured by Western blot assay.
Website: https://www.selleckchem.com/products/hg-9-91-01.html